SCHEMBL26906797

SCHEMBL26906797

CNS(=O)(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)nc2OC)ncc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 16/20 0.68
▸ INSR P06213 11/20 0.68
▸ IGF1R P08069 10/20 0.68
▸ ROS1 P08922 7/20 0.67
▸ EGFR P00533 6/20 0.64
▸ FGFR1 P11362 3/20 0.64
▸ FGFR2 P21802 3/20 0.64
▸ FGFR4 P22455 3/20 0.64
▸ FGFR3 P22607 3/20 0.64
▸ MET P08581 3/20 0.64
▸ CHEK1 O14757 2/20 0.64
▸ AURKA O14965 2/20 0.64
▸ NUAK1 O60285 2/20 0.64
▸ JAK2 O60674 2/20 0.64
▸ STK10 O94804 2/20 0.64
▸ PRKD3 O94806 2/20 0.64
▸ CHEK2 O96017 2/20 0.64
▸ ABL1 P00519 2/20 0.64
▸ ERBB2 P04626 2/20 0.64
▸ LCK P06239 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29114861 0.93 ALK (0.66) ALKINSRIGF1RROS1EGFR
SCHEMBL26906710 0.88 ALK (0.65) ALKINSRIGF1RROS1EGFR
SCHEMBL29904662 0.88 ALK (0.65) ALKINSRIGF1RROS1EGFR
SCHEMBL26906661 0.88 ALK (0.87) ALKINSRIGF1RROS1EGFR
SCHEMBL29904684 0.87 ALK (0.60) ALKINSRIGF1RROS1EGFR
SCHEMBL26906730 0.87 ALK (0.60) ALKINSRIGF1RROS1EGFR
SCHEMBL12893070 0.86 EGFR (0.54) ALKINSRIGF1RROS1EGFR
SCHEMBL29904644 0.86 ALK (0.68) ALKINSRIGF1RROS1EGFR
SCHEMBL22462106 0.85 INSR (0.77) ALKINSRIGF1RROS1EGFR
SCHEMBL29904620 0.85 ZAP70 (0.66) ALKINSRIGF1RROS1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP claimed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed
CN-117120424-A Pyrimidine derivatives having protein kinase inhibitory activity and therapeutic combinations comprising the same 泰拉佩克斯有限公司 2023-11-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 ALK 120/4885INSR 607/4885IGF1R 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback